This study demonstrates for the first time, a successful study of three small cell neuroendocrine prostate cancer patient derived xenografts (PDX) models in liver and bone in pre-clinical setting. Kidney served as an optimum site for propagation with its rich blood supply and high take rate. Hyperpolarized 13C MRI was able to identify metabolic differences between kidney, bone and liver tumors. The same PDXs had different metabolism when implanted in bone and liver. Hyperpolarized [1-13C] pyruvate conversion to lactate may be used to indicate early response to carboplatin in small cell neuroendocrine prostate cancer models in the bone.